›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
RocheType:
FDA Approved
Related tests:
VENTANA Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (VENTANA HER2 (4B5)) is intended for the semi-quantitative detection of HER2 antigen in sections of formalin-fixed, paraffin-embedded normal and neoplastic breast and gastric tissue on a VENTANA automated IHC/ISH slide staining device. It is indicated as an aid in the assessment of breast and gastric cancer patients for whom Herceptin treatment is considered and for breast cancer patients for whom Kadcyla (trastuzumab emtansine) or Perjeta (pertuzumab) treatments are being considered.
Cancer:
Breast Cancer, Gastric Cancer
Gene:
HER-2 (Human epidermal growth factor receptor 2)
HER-2 (Human epidermal growth factor receptor 2)
Drug:
Enhertu (fam-trastuzumab deruxtecan-nxki), Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab)
Method:
Immunohistochemistry (IHC)
Approvals
Date
Cancer
Gene
Biomarker
Drug
Approved by
09/30/2022
FDA Approved
Approvals
Date
Cancer
Gene
Drug
By
